Alex joined PrimeVigilance in 2022 and he oversees the development of innovation and corrective/disruption strategies to drive growth and spur investment.
Alex brings more than 18 years of drug development expertise in multiple technologies, therapeutic indications and clinical phases involving NCEs, biologics, combination products and ATMPs. His contributions have been strategic – helping to position biotech companies for future growth and operational optimization – as well as scientific, through consulting clients during pre-, peri- and post- marketing approval.
Prior to joining PrimeVigilance, Alex held regulatory affairs consulting and leadership positions in small and mid-size CROs and has worked for global organisations such as Wockhardt Group in Ireland, Biotronik AG and Vifor Pharma Ltd in Switzerland.
Alex commenced his career as a researcher at Carnegie Mellon University, USA, following his doctoral studies in macromolecular/organic chemistry at Lancaster University, UK.
